賽生藥業(06600.HK):建議以協議安排方式私有化及撤銷公司上市地位 4月2日起復牌
格隆匯3月28日丨德福資本及賽生藥業(06600.HK)聯合公吿,2024年3月19日,要約人(即Silver Pegasus Investment Limited,一間在開曼羣島註冊成立的獲豁免有限公司)就根據公司法第86條以協議安排方式將公司私有化,要求董事會向計劃股份持有人提呈建議,其中涉及註銷計劃股份,作為代價,就每股計劃股份以現金向計劃股東支付註銷價,並撤銷股份於聯交所的上市地位。
計劃將訂明,計劃股份將予註銷,以換取每股計劃股份現金18.8港元。存續股份將不會構成計劃股份的一部分,亦不會被註銷。計劃生效後,根據存續協議,存續股份將轉讓予要約人,代價為Topco(其全資擁有要約人)將按註銷價向存續股東發行的合共約2.09億股入賬列作繳足的股份。計劃完成及根據存續協議轉讓存續股份後,公司將由要約人全資擁有。
註銷價18.8港元較不受干擾日期在聯交所所報收市價每股14.04港元溢價約33.90%。最後交易日的交易量為974.15萬股。不受干擾期間的平均每日交易量為203.5萬股。公司股價在最後交易日上升14.25%。相比之下,恒生指數在最後交易日上升0.10%。
悉數行使目標購股權會導致發行5442.1萬股新股份,佔公司於公吿日期的已發行股本約8.67%及經發行有關新股份擴大後已發行股本約7.98%。要約人將向購股權持有人作出(或促使代其作出)適當要約,以根據收購守則規則13註銷所有已歸屬及未歸屬目標購股權。購股權要約須於計劃生效後方可作實。
要約人擬透過來自GL Canadian Fund及GL Cayman Fund的具約束力股權承諾函件以及外部債務融資撥付建議的現金需求。此外,GL Canadian Fund及GL Cayman Fund有一般資金信貸額度,並已準備額外內部現金資源支持彼等對要約人的股權承諾。要約人有關建議的財務顧問中金公司信納要約人具備充足的財務資源,以履行其建議項下應付現金代價的付款義務。
董事會已設立由公司全體獨立非執行董事(即劉國恩博士、Chen Ping博士、 Gu Alex Yushao先生及Wendy Hayes女士)組成的獨立董事委員會。經獨立董事委員會批准後,董事會已委任創富融資為獨立財務顧問,以根據收購守則規則2.1就建議、計劃、購股權要約及存續安排向獨立董事委員會提供意見。計劃生效後,所有計劃股份將予註銷,且計劃股份的任何股份證書於其後將不再具有所有權文件或證據的效力。公司將於計劃生效後立即根據上市規則第6.15(2)條向聯交所申請撤銷股份於聯交所的上市地位。
應公司要求,股份於2024年3月19日上午9時07分暫停於聯交所買賣,以待刊發本公吿。公司已向聯交所申請復牌,於2024年4月2日上午九時正起恢復股份於聯交所的買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.